Overview

A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body

Status:
Terminated
Trial end date:
2018-10-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company